|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LGR6 |
Gene summary for LGR6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LGR6 | Gene ID | 59352 |
| Gene name | leucine rich repeat containing G protein-coupled receptor 6 | |
| Gene Alias | GPCR | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9HBX8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 59352 | LGR6 | P2T-E | Human | Esophagus | ESCC | 3.42e-12 | 5.05e-01 | 0.1177 |
| 59352 | LGR6 | P4T-E | Human | Esophagus | ESCC | 1.05e-06 | 3.65e-01 | 0.1323 |
| 59352 | LGR6 | P8T-E | Human | Esophagus | ESCC | 4.48e-04 | 1.15e-01 | 0.0889 |
| 59352 | LGR6 | P9T-E | Human | Esophagus | ESCC | 4.56e-05 | 1.34e-02 | 0.1131 |
| 59352 | LGR6 | P10T-E | Human | Esophagus | ESCC | 2.08e-45 | 9.68e-01 | 0.116 |
| 59352 | LGR6 | P11T-E | Human | Esophagus | ESCC | 4.73e-02 | 1.41e-01 | 0.1426 |
| 59352 | LGR6 | P12T-E | Human | Esophagus | ESCC | 4.66e-03 | 1.99e-01 | 0.1122 |
| 59352 | LGR6 | P15T-E | Human | Esophagus | ESCC | 6.58e-09 | 4.55e-01 | 0.1149 |
| 59352 | LGR6 | P16T-E | Human | Esophagus | ESCC | 3.32e-69 | 2.20e+00 | 0.1153 |
| 59352 | LGR6 | P21T-E | Human | Esophagus | ESCC | 7.14e-03 | 2.08e-01 | 0.1617 |
| 59352 | LGR6 | P27T-E | Human | Esophagus | ESCC | 3.12e-11 | 2.69e-01 | 0.1055 |
| 59352 | LGR6 | P28T-E | Human | Esophagus | ESCC | 1.46e-06 | 1.00e-01 | 0.1149 |
| 59352 | LGR6 | P30T-E | Human | Esophagus | ESCC | 4.21e-14 | 7.95e-01 | 0.137 |
| 59352 | LGR6 | P31T-E | Human | Esophagus | ESCC | 3.49e-04 | 1.66e-01 | 0.1251 |
| 59352 | LGR6 | P56T-E | Human | Esophagus | ESCC | 6.32e-12 | 2.89e+00 | 0.1613 |
| 59352 | LGR6 | P57T-E | Human | Esophagus | ESCC | 1.79e-05 | 3.96e-01 | 0.0926 |
| 59352 | LGR6 | P62T-E | Human | Esophagus | ESCC | 3.11e-06 | 1.76e-01 | 0.1302 |
| 59352 | LGR6 | P65T-E | Human | Esophagus | ESCC | 1.27e-06 | 2.02e-01 | 0.0978 |
| 59352 | LGR6 | P107T-E | Human | Esophagus | ESCC | 3.82e-02 | 3.65e-02 | 0.171 |
| 59352 | LGR6 | P127T-E | Human | Esophagus | ESCC | 5.47e-04 | 1.80e-02 | 0.0826 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:006082817 | Esophagus | ESCC | regulation of canonical Wnt signaling pathway | 153/8552 | 253/18723 | 1.38e-06 | 1.67e-05 | 153 |
| GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
| GO:009026316 | Esophagus | ESCC | positive regulation of canonical Wnt signaling pathway | 69/8552 | 106/18723 | 4.22e-05 | 3.39e-04 | 69 |
| GO:003017716 | Esophagus | ESCC | positive regulation of Wnt signaling pathway | 87/8552 | 140/18723 | 6.18e-05 | 4.73e-04 | 87 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LGR6 | SNV | Missense_Mutation | novel | c.1312N>T | p.Pro438Ser | p.P438S | Q9HBX8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| LGR6 | SNV | Missense_Mutation | rs141363260 | c.1762G>A | p.Ala588Thr | p.A588T | Q9HBX8 | protein_coding | tolerated(0.26) | benign(0.044) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| LGR6 | SNV | Missense_Mutation | rs140358092 | c.2411C>T | p.Thr804Met | p.T804M | Q9HBX8 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LGR6 | SNV | Missense_Mutation | c.755N>T | p.Ala252Val | p.A252V | Q9HBX8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| LGR6 | SNV | Missense_Mutation | c.647A>T | p.His216Leu | p.H216L | Q9HBX8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| LGR6 | insertion | Nonsense_Mutation | novel | c.2826_2827insCTGAGAGAAACAGAGCCTCAGGCATAGACTGGTTAC | p.Gly942_Ser943insLeuArgGluThrGluProGlnAlaTerThrGlyTyr | p.G942_S943insLRETEPQA*TGY | Q9HBX8 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| LGR6 | SNV | Missense_Mutation | novel | c.2222C>T | p.Ser741Phe | p.S741F | Q9HBX8 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LGR6 | SNV | Missense_Mutation | c.1525N>G | p.Lys509Glu | p.K509E | Q9HBX8 | protein_coding | deleterious(0.01) | possibly_damaging(0.576) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LGR6 | SNV | Missense_Mutation | c.2217N>A | p.Met739Ile | p.M739I | Q9HBX8 | protein_coding | deleterious(0.05) | benign(0.027) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LGR6 | SNV | Missense_Mutation | novel | c.914C>T | p.Pro305Leu | p.P305L | Q9HBX8 | protein_coding | deleterious(0) | benign(0.388) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178102181 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178101191 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178100586 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178102183 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178100587 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178100588 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178100589 | ||
| 59352 | LGR6 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 178102182 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |